journal
https://read.qxmd.com/read/37731392/prehistory-of-chronic-lymphocytic-leukemia-clues-from-the-b-cell-receptor
#1
JOURNAL ARTICLE
Frederic Davi
Not available.
September 21, 2023: Haematologica
https://read.qxmd.com/read/37731390/outcome-heterogeneity-of-tp53-mutated-myeloid-neoplasms-and-the-role-of-allogeneic-hematopoietic-cell-transplantation
#2
JOURNAL ARTICLE
Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, Jonathan A Webster, Tania Jain, W Brian Dalton, Gabrielle T Prince, Gabriel Ghiaur, Amy E DeZern, Ivana Gojo, B Douglas Smith, Theodoros Karantanos, Cory Schulz, Kristin Stokvis, Mark J Levis, Richard J Jones, Lukasz P Gondek
Not available.
September 21, 2023: Haematologica
https://read.qxmd.com/read/37731389/dabrafenib-and-trametinib-in-langerhans-cell-histiocytosis-and-other-histiocytic-disorders
#3
JOURNAL ARTICLE
Eily Cournoyer, Justin Ferrell, Susan Sharp, Anish Ray, Michael Jordan, Christopher Dandoy, Michael Grimley, Somak Roy, Robert Lorsbach, Arnold C Merrow, Adam Nelson, Allison Bartlett, Jennifer Picarsic, Ashish Kumar
Standard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dabrafenib and/or trametinib, either as first line or after relapse or failure of chemotherapy...
September 21, 2023: Haematologica
https://read.qxmd.com/read/37731380/immune-checkpoint-molecule-dnam-1-cd112-axis-is-a-novel-target-for-nk-cell-therapy-in-acute-myeloid-leukemia
#4
JOURNAL ARTICLE
Yuta Kaito, Emi Sugimoto, Fumi Nakamura, Yutaka Tsukune, Makoto Sasaki, Shunsuke Yui, Hiroki Yamaguchi, Susumu Goyama, Yasuhito Nannya, Kinuko Mitani, Hideto Tamura, Yoichi Imai
Acute myeloid leukemia (AML) is a hematological malignancy that frequently relapses, even if remission is achieved with intensive chemotherapy. One known relapse mechanism is the escape of leukemic cells from immune surveillance. Currently, there is no effective AML immunotherapy owing to the lack of specific antigens. Here, we aimed to elucidate the association between CD155 and CD112 in AML cell lines and primary AML samples and their therapeutic response. Briefly, we generated NK-92 cell lines (NK-92) with modified DNAX-associated molecule 1 (DNAM-1) and T-cell immunoglobulin and ITIM domain (TIGIT), which are receptors of CD155 and CD112, respectively...
September 21, 2023: Haematologica
https://read.qxmd.com/read/37731379/idecabtagene-vicleucel-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-refractory-multiple-myeloma-with-renal-impairment
#5
JOURNAL ARTICLE
Surbhi Sidana, Lauren C Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David Miklos, Charlotte Wagner, Mehmet H Kocoglu, Gurbakhash Kaur, James A Davis, Shonali Midha, Murali Janakiram, Ciara Freeman, Melissa Alsina, Frederick Locke, Rebecca Gonzalez, Yi Lin, Joseph McGuirk, Aimaz Afrough, Leyla Shune, Krina K Patel, Doris K Hansen
We evaluated patients with relapsed multiple myeloma with renal impairment (RI treated with standard of care ide-cel, as outcomes with CAR-T therapy are unknown in this population. RI was defined as creatinine clearance (CrCl < 50 ml/min. CrCl of < 30 ml/min or dialysis dependence were defined as severe RI. The study cohort included 214 patients, 28 (13% patients with RI, including 11 patients severe RI (dialysis, n=1. Patients with RI were older, more likely to be female and had higher likelihood of having R-ISS stage 3 disease...
September 21, 2023: Haematologica
https://read.qxmd.com/read/37731378/iron-deficiency-responses-and-integrated-compensations-in-patients-according-to-hereditary-haemorrhagic-telangiectasia-acvrl1-eng-and-smad4-genotypes
#6
JOURNAL ARTICLE
Lakshya Sharma, Fatma Almaghlouth, Heidi Mckernan, James Springett, Hannah C Tighe, Claire L Shovlin
Not available.
September 21, 2023: Haematologica
https://read.qxmd.com/read/37731369/bone-mineral-density-in-adult-patients-with-pyruvate-kinase-deficiency-on-long-term-mitapivat-treatment
#7
JOURNAL ARTICLE
Hanny Al-Samkari, Rachael F Grace, Andreas Glenthøj, Oliver Andres, Wilma Barcellini, Frédéric Galacteros, Kevin H M Kuo, D Mark Layton, Marta Morado, Vip Viprakasit, Feng Tai, Rolandas Urbstonaitis, Jaime Morales, Bryan McGee, Eduard J van Beers
Not available.
September 21, 2023: Haematologica
https://read.qxmd.com/read/37706363/ultra-deep-mutational-landscape-in-chronic-lymphocytic-leukemia-uncovers-dynamics-of-resistance-to-targeted-therapies
#8
JOURNAL ARTICLE
David W Woolston, Nathan D Lee, Mazyar Shadman, Elena Latorre-Esteves, Xin Ray Tee, Jeanne Fredrickson, Brendan F Kohrn, Chaitra Ujjani, Ashley Eckel, Brian Till, Min Fang, Jerald Radich, Ivana Bozic, Rosa Ana Risques, Cecilia C S Yeung
BTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL). With increased survivorship, monitoring disease and deciphering potential mechanisms of resistance to these agents are critical for devising effective treatment strategies. We used duplex sequencing, a technology that enables detection of mutations at ultra-low allelic frequencies, to identify mutations in five genes associated with drug resistance in CLL and followed their evolution in two patients who received multiple targeted therapies and ultimately developed disease progression on pirtobrutinib...
September 14, 2023: Haematologica
https://read.qxmd.com/read/37706355/treg-targeted-il-2-anti-il-2-complex-controls-graft-versus-host-disease-and-supports-anti-tumor-effect-in-allogeneic-hematopoietic-stem-cell-transplantation
#9
JOURNAL ARTICLE
Allan Thiolat, Caroline Pilon, Pamela Caudana, Audrey Moatti, Nhu Hanh To, Christine Sedlik, Mathieu Leclerc, Sébastien Maury, Eliane Piaggio, José L Cohen
Modulating an immune response in opposite directions represents the holy grail in allogeneic hematopoietic stem cell transplantation (allo-HSCT) to avoid insufficient reactivity of donor T cells and hematologic malignancy relapse while controlling the potential development of graft-versus-host disease (GVHD), in which donor T cells attack the recipient's tissues. IL-2/anti-IL-2 complexes (IL2-Cxs) represents a therapeutic option to selectively accentuate or dampen the immune response. In dedicated experimental models of allo-HSCT, including also human cells injected in immunodeficient NSG mice, we evaluated side-by-side the therapeutic effect of two IL-2Cxs designed either to boost regulatory T cells (Tregs) or alternatively to activate effector T cells (Teffs), on GVHD occurrence and tumor relapse...
September 14, 2023: Haematologica
https://read.qxmd.com/read/37706344/prognostic-value-of-european-leukemia-net-2022-criteria-and-genomic-clusters-using-machine-learning-in-older-adults-with-acute-myeloid-leukemia
#10
JOURNAL ARTICLE
Silvia Park, Tong Yoon Kim, Byung-Sik Cho, Daehun Kwag, Jong-Mi Lee, MyungShin Kim, Yonggoo Kim, Jamin Koo, Anjali Raman, Tae Kon Kim, Hee-Je Kim
This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic risk stratification in older adults with acute myeloid leukemia (AML) and to determine the most likely set of clusters of similar cytogenetic and mutation properties correlated with survival outcomes in three treatment groups: intensive chemotherapy (IC), hypomethylating agents (HMAs) alone, and HMAs plus venetoclax (HMA/VEN). The study included 279 patients (≥60 years) who received IC (n=131), HMA (n=76), and HMA/VEN (n=72) between July 2017 and October 2021...
September 14, 2023: Haematologica
https://read.qxmd.com/read/37706343/somatic-variant-profiling-in-chronic-phase-pediatric-chronic-myeloid-leukemia
#11
JOURNAL ARTICLE
Yvonne Lisa Behrens, Laura Gaschler, Ronny Nienhold, Thea Reinkens, Elke Schirmer, Sabine Knöß, Renate Strasser, Stephanie Sembill, Zofia Wotschofsky, Meinolf Suttorp, Manuela Krumbholz, Brigitte Schlegelberger, Markus Metzler, Gudrun Göhring, Axel Karow
Not available.
September 14, 2023: Haematologica
https://read.qxmd.com/read/37706336/a-phase-ii-study-of-interrupted-and-continuous-dose-lenalidomide-in-relapsed-refractory-hodgkin-lymphoma
#12
JOURNAL ARTICLE
Todd A Fehniger, Marcus P Watkins, Nkiruka Ezenwajiaku, Fei Wan, David D Hurd, Amanda F Cashen, Kristie A Blum, Andre Goy, Timothy S Fenske, Nina D Wagner-Johnston, Kenneth Carson, Marilyn J Siegel, David Russler-Germain, Stephanie E Schneider, Neha Mehta-Shah, Brad Kahl, Nancy L Bartlett
Not available.
September 14, 2023: Haematologica
https://read.qxmd.com/read/37706335/daratumumab-and-brentuximab-vedotin-combination-therapy-in-t-cell-acute-lymphoblastic-leukemia-refractory-to-conventional-chemotherapy-and-allogeneic-stem-cell-transplant
#13
JOURNAL ARTICLE
Kebede H Begna, Nadine H Abdallah, Michelle Janania-Martinez, Abhishek A Mangaonkar, Aruna Rangan, Jennifer L Herrick, Naseema Gangat
Not available.
September 14, 2023: Haematologica
https://read.qxmd.com/read/37706332/oligosecretory-waldenstrom-macroglobulinemia-exhibits-excellent-treatment-response-and-outcomes
#14
JOURNAL ARTICLE
Wenjie Xiong, Ying Yu, Chunyan Sun, Juan Du, Zhen Cai, Zanzan Wang, Xinxin Cao, Yuting Yan, Jiawen Chen, Yanshan Huang, Zhongxing Jiang, Huihan Wang, Ting Niu, Guangzhong Yang, Hua Xue, Bingzong Li, Honghui Huang, Zhenling Li, Qinhua Liu, Fei Li, Ou Bai, Min Mao, Rong Fu, Ling Wang, Chunrui Li, Xiaoxia Chu, Lihong Liu, Yujun Dong, Luqun Wang, Jun Luo, Yongqiang Wei, Rui Cui, Lugui Qiu, Jian Li, Shuhua Yi
Not available.
September 14, 2023: Haematologica
https://read.qxmd.com/read/37706330/amphiregulin-as-monitoring-biomarker-for-life-threatening-acute-graft-versushost-disease-secondary-analysis-of-two-prospective-clinical-trials
#15
JOURNAL ARTICLE
Shernan G Holtan, Najla El Jurdi, Armin Rashidi, Brian C Betts, Connor Demorest, John P Galvin, Margaret L MacMillan, Daniel J Weisdorf, Angela Panoskaltsis-Mortari, Michael A Pratta
Not available.
September 14, 2023: Haematologica
https://read.qxmd.com/read/37706315/diffuse-large-b-cell-lymphoma-involving-the-central-nervous-system-biologic-rationale-for-targeted-therapy
#16
JOURNAL ARTICLE
Mark Roschewski, Daniel J Hodson
Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable for all patients, and older patients have fewer effective treatment options...
September 14, 2023: Haematologica
https://read.qxmd.com/read/37675517/expanding-treatment-options-by-selectively-targeting-the-cytokine-storm-with-ruxolitinib-in-primary-hemophagocytic-lymphohistiocytosis
#17
JOURNAL ARTICLE
https://read.qxmd.com/read/37675516/uniform-conditioning-regardless-of-donor-in-bone-marrow-transplantation-for-severe-aplastic-anemia
#18
JOURNAL ARTICLE
Amy E DeZern, Marianna Zahurak, Richard J Jones, Robert A Brodsky
Not available.
September 7, 2023: Haematologica
https://read.qxmd.com/read/37675514/immune-mediated-facial-nerve-paralysis-in-a-myeloma-patient-post-b-cell-maturation-antigen-targeted-chimeric-antigen-receptor-t-cells
#19
JOURNAL ARTICLE
Yamini K Kathari, Haroon Ahmad, Michael E Kallen, Rima Koka, Destiny Omili, Thierry Iraguha, Jean Clement, Lily Pham, Mazhar Khalid, Xiaoxuan Fan, Etse Gebru, Patricia Lesho, Esther Park, Nishanthini Dishanthan, Jillian M Baker, Kenneth A Dietze, Kim G Hankey, Ashraf Badros, Jean A Yared, Saurabh Dahiya, Nancy M Hardy, Hakan Kocoglu, Tim Luetkens, Aaron P Rapoport, Djordje Atanackovic
Not available.
September 7, 2023: Haematologica
https://read.qxmd.com/read/37675513/frequent-high-density-expression-of-surface-cd38-as-a-potential-therapeutic-target-in-adult-t-lineage-acute-lymphoblastic-leukemia
#20
JOURNAL ARTICLE
Sebastian Koslowski, Rainer Glauben, Stefan Habringer, Thomas Burmeister, Ulrich Keller, Monika Brüggemann, Nicola Gökbuget, Stefan Schwartz
Not available.
September 7, 2023: Haematologica
journal
journal
24858
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.